Tirzepatide (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once weekly subcutaneously on the same day each week. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects. Higher doses (12.5 to 15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.

Reconstitution Steps

1. Draw 2.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
5. Use within 28 days of reconstitution. At 5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions; minimize moisture exposure.
• Reconstituted: refrigerate at 2 to 8 °C; do not freeze reconstituted solution.
• Shelf life: use reconstituted solution within 28 days.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week protocol with gradual titration (once-weekly dosing).

Peptide Vials (Tirzepatide, 10 mg each):

• 8 weeks (2.5 to 5 mg/wk): ~30 mg total » 3 vials.
• 12 weeks (2.5 to 7.5 mg/wk): ~60 mg total » 6 vials.
• 16 weeks (2.5 to 10 mg/wk): ~100 mg total » 10 vials.

Insulin Syringes (U-100, 1 mL):

• 8 weeks: 8 syringes (1/week).
• 12 weeks: 16 syringes (~1.3/week avg).
• 16 weeks: 24 syringes (~1.5/week avg).

Bacteriostatic Water (10 mL bottles):

• 8 weeks (3 vials): 1 bottle. 12 weeks (6 vials): 2 bottles. 16 weeks (10 vials): 2 bottles.

Alcohol Swabs:

• Per week: 2 swabs. 16 weeks: 32 swabs (1 x 100-count box).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• For multi-injection doses, use different sites for each injection on the same day.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document weekly dose, date, and injection site to maintain consistency.
• Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them.

How This Works

Tirzepatide is a novel dual agonist that simultaneously activates GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose-dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP-1 alone, contributing to superior weight reduction observed in clinical trials. Its approximately 5 day half-life enables convenient once-weekly administration.

Benefits & Side Effects

Observations from clinical trials and published literature.

• Glycemic control: Significant HbA1c reductions in type 2 diabetes trials.
• Weight reduction: Clinical trials report substantial body-weight loss (up to ~11 kg more than GLP-1 RA

comparators over 26 weeks at higher doses).

• Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.
• Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation), typically mild to

moderate and dose-dependent; gradual titration reduces incidence.

• Injection-site reactions: Occasional mild redness or irritation at subcutaneous injection sites.

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, calorie-appropriate diet; reduced appetite may naturally decrease intake.
• Prioritize protein to preserve lean mass during weight loss.
• Combine resistance training and aerobic activity to support metabolic health.
• Stay hydrated, especially given potential gastrointestinal effects.
• Prioritize sleep and stress management to support adherence and recovery.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen avoiding 2-inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy.
5. Dispose of needles and syringes in a sharps container immediately after use.

References

Source citations for further reading.

1. Farzam K, Patel P. Tirzepatide (StatPearls / NCBI Bookshelf, 2024).
2. Gallwitz B. GIP/GLP-1 receptor agonist Tirzepatide for type 2 diabetes and obesity (Frontiers in Endocrinology, 2022).
3. Frias JP, et al. Efficacy and safety of LY3298176 (Tirzepatide) Phase 2 trial (The Lancet, 2018).
4. Jastreboff AM, et al. Tirzepatide once weekly for treatment of obesity (NEJM, 2022).